| First Author | Iidaka T | Year | 2005 |
| Journal | Cancer Lett | Volume | 217 |
| Issue | 2 | Pages | 149-59 |
| PubMed ID | 15617832 | Mgi Jnum | J:95218 |
| Mgi Id | MGI:3525715 | Doi | 10.1016/j.canlet.2004.07.015 |
| Citation | Iidaka T, et al. (2005) Lack of elevated liver carcinogenicity of aminophenylnorharman in p53-deficient mice. Cancer Lett 217(2):149-59 |
| abstractText | The hepatocarcinogenic potential of 9-(4'-aminophenyl)-9H-pyrido[3,4-b]indole (aminophenylnorharman, APNH) was investigated using male and female p53 deficient mice. Incidence of oval cell hyperplasia was 2/14 (14.3%), 14/23 (60.9%), and 2/10 (20%) in p53 nullizygous (-/-), heterozygous (+/-), and wild type (+/+) mice, respectively, exposed to 30ppm APNH for 15 weeks, while hepatocellular anisonucleosis was observed only in APNH-treated p53 (-/-) mice. At 40 weeks, hepatocellular carcinomas had developed in 16/46 (34.8%) and 10/27 (37.0%) of female p53 (+/-) and (+/+) mice in contrast to only 1/45 (2.2%) and 2/12 (16.7%) in their male counterparts, respectively, without any detectable p53 gene mutations. Dose-dependent APNH-DNA adduct formation and transcriptional induction of CYP 1A1, but not CYP 1A2, was revealed with 7-day APNH treatment using female C57BL/6J mice. These results suggested hepatocarcinogenicity of APNH in mice could be linked to the liver microenvironment including hormonal milieu but independent of p53 expression and p53 gene mutations. |
